Department of Psychiatry, Public Assistance Marseille Hospitals, Sainte Marguerite University Hospital.
Imothep Team, Fresnel Institute, UMR 7249, Aix-Marseille University, CNRS, Ecole Centrale Marseille, France.
Int Clin Psychopharmacol. 2024 Sep 1;39(5):323-325. doi: 10.1097/YIC.0000000000000482. Epub 2023 Jul 11.
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD received an acute course of intranasal esketamine (84 mg). Previously, 14 different antidepressants, alone or in potentiation, and several neurostimulation techniques had been unsuccessful. Over 20 bi-weekly sessions, she had no significant adverse effects and was stabilized into remission. During the maintenance phase and 1 year after, she continues to be stable. This case report provides an example of a patient with severe TRD that showed significant improvement after treatment with intranasal esketamine.
约 30%的重性抑郁障碍患者存在治疗抵抗性抑郁（TRD）。最近，鼻内应用艾司氯胺酮在两项抗抑郁药试验失败后被批准作为一种治疗选择。我们报告了一例使用鼻内艾司氯胺酮成功且安全治疗的多药抵抗性抑郁患者。这名 31 岁的住院患者患有严重、慢性和多种 TRD，接受了急性鼻内艾司氯胺酮（84mg）治疗。此前，已使用 14 种不同的抗抑郁药（单独或增效）和几种神经刺激技术，但均不成功。经过 20 多次双周治疗，她没有出现明显的不良反应，并稳定缓解。在维持治疗阶段和 1 年后，她仍然稳定。本病例报告提供了一个严重 TRD 患者的例子，该患者在接受鼻内艾司氯胺酮治疗后显示出显著改善。
